Concord Biotech IPO opens. Should you subscribe to the issue?

August 4, 2023

Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client relationship and high entry barriers. The company is one of the leading global manufacturers of select fermentation-based APIs (F-APIs) across immunosuppressants and oncology with a market share of over 20% by volume in 2022.

More To Explore

Updater Services IPO to open on September 25. Here are 10 things to know about the offer

The company offers integrated facilities management (IFM) services and business support services to its customers, with a pan-India presence. Its portfolio of services evolved over

September 24, 2023

JSW Infra’s Rs 2,800-crore IPO to open on Monday. Here are 10 things to know about the offer

The IPO is entirely a fresh equity issue of Rs 2,800 crore. This is the first IPO from a JSW Group company in 13 years

September 24, 2023

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

Generated by Feedzy